A systematic review and meta-analysis of the Cochrane Library published in 2018, which included 8 RCTs for a total of 817 eyes (the majority of which using bevacizumab plus TA), showed that the combination of IV anti-VEGF and steroids does not appear to provide additional visual benefit compared to monotherapy, exposing the patients to the potential side effects of both agents, such as cataract, glaucoma, stroke, and heart attack [183]. Here, VEGFA is linked to myocardial infarction.